Breaks Categories: News

WednesdayMay 04, 2022 1:50 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Launches New Skincare Line Ahead of Luxury Meets Cannabis Conference

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, today announced the launch of a new skincare line under its brand, MIND Naturals (“Mind”), ahead of the Luxury Meets Cannabis Conference (“LMCC”) in New York City. Mind is inspired by its Colombian roots and leverages superfruits and nutrients native to Colombia for its new non-CBD line of skincare products. “This is a very exciting launch from MIND Naturals and Flora - the U.S. skincare market alone presents a unique opportunity for growing all-natural skincare brands, with annual revenue of approximately $17.6 billion,” said Flora…

Continue Reading

WednesdayMay 04, 2022 1:36 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Transition from Pure-Play Pharma R&D Firm Featured in Research Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, was featured in a report published by Edison Group, a leading research and investor relations consultancy. The piece details InMed Pharmaceuticals and its continued “transition from a pure-play pharma R&D firm to one also benefiting from commercial sales into the health and wellness market. Product launches of high-value, rare cannabinoids into this market should provide the majority of its revenue in the near future,” the report reads. “INM also made notable advances in its pharmaceutical drug development programs, including its ongoing 755-201-EB Phase II…

Continue Reading

FridayApr 29, 2022 10:59 am

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) to Participate in Luxury Meets Cannabis Conference

Flora Growth’s (NASDAQ: FLGC) executives Luis Merchan and James Choe are scheduled to participate at the upcoming Luxury Meets Cannabis Conference. The two-day event is scheduled for May 5–6, 2022, in New York City. The premier B2B CBD, hemp and cannabis event — the first of its kind — is an ideal venue to shine a spotlight on FLGC’s impressive line of lifestyle products and brands. The conference is designed to bring together premium CBD, hemp and cannabis brands and their founders with representatives from top mainstream retailers, global media, leading dispensaries and investors. Flora Growth is a leading all-outdoor cannabis cultivator…

Continue Reading

ThursdayApr 28, 2022 12:50 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Patent Portfolio with Novel Cannabinoid Analogs, Initiates Strategic Research Collaboration Agreement

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced the publication of a patent application in North America. The application has broad claims directed to the molecular structure, uses and methods of manufacturing of several cannabinoid analogs. Describing several new cannabinoid-related chemical compounds, the broad patent application, if granted, allows for the creation of several variations of novel cannabinoid compounds, producing a robust library of proprietary new chemical entities (“NCEs”). “We believe rare cannabinoids hold tremendous therapeutic potential that may address a number of unmet medical needs,” said Eric Hsu, SVP,…

Continue Reading

ThursdayApr 28, 2022 12:29 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Achieves Integration Milestone with First-Ever Sourcing of Its CBD into Market-Ready Products

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of cannabis products and brands, today announced that it has formally begun the integration of its licensed and Control Union Medical Cannabis Standard GACP (“CUMCS-GACP”) certified cannabis products and derivatives into its global roster of branded products. Beginning with CBD derivatives used in Mind Naturals, its award-winning skincare brand, the company has begun the process of integrating significantly lower-cost cannabinoids, grown and extracted at Flora’s cultivation and extraction facility, Cosechemos, for products formulated at the company’s GMP-licensed laboratory in Bogota, Colombia. The move marks a milestone in the company’s integration strategy,…

Continue Reading

TuesdayApr 26, 2022 1:19 pm

CannabisNewsBreaks – RYAH Group Inc. (CSE: RYAH) Names New CFO, Corporate Secretary

RYAH Group (CSE: RYAH), a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry, has announced the appointment of a new chief financial officer and corporate secretary. The company named François C. Desrosiers, B. Com (Spec.) and FCSI, as Rryah CFO and corporate; the appointment is subject to approval  by the Canadian Securities Exchange (“CSE”). Desrosiers brings impressive experience in senior executive leadership roles to his new role with RYAH. He has served as cofounder, president, CEO and director at Northcore Resources Inc.; corporate secretary and officer…

Continue Reading

ThursdayApr 21, 2022 2:07 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures First-Ever Patent for DehydraTECH to Deliver Antiviral Drugs

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of its first-ever patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs. According to the update, Lexaria has received notification from the United States Patent and Trademark Office that patent 11,311,559 for “Compositions and Methods for Enhanced Delivery of Antiviral Agents” will be issued to the company on April 26, 2022. “This will be our 25th patent granted worldwide and another validation of the versatility of our DehydraTECH drug delivery technology,” said Chris Bunka, CEO of Lexaria. “This new…

Continue Reading

ThursdayApr 21, 2022 12:22 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Expansion of Rare Cannabinoid Portfolio

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is launching business-to-business sales of its rare cannabinoid cannabidivarin (“CBDV”). Through subsidiary BayMedica LLC, InMed will offer its product to wholesalers, suppliers and end-product manufacturers in the health and wellness sector. In addition, the company released a white paper focused on research into the therapeutic potential of CBDV. According to the announcement, CBDV is a nonintoxicating rare cannabinoid that is similar to CBD but offers important differences in activity. One of the most-studied rare cannabinoids, CBDV is currently the focus of several different clinical…

Continue Reading

WednesdayApr 20, 2022 1:22 pm

CannabisNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Provides Update Regarding Restructuring, Strengthening of Balance Sheet

Red White & Bloom (CSE: RWB) (OTCQX: RWBYF), a multistate cannabis operator and house of premium brands, has completed a companywide restricting, which resulted in the elimination of $115 million in liabilities and more than $22 million in annual expenses. Highlights of the strategic moves include the completion of the sale of its Granville, Illinois, facility; the repayment of $51.7 million secured debt and the elimination of $6.3 million of annualized debt servicing; and transitioning to an asset-light, brand-rich model that eliminated more than $13 million in associated annual operating expenses, inclusive of $8 million in cash operating costs. In…

Continue Reading

TuesdayApr 19, 2022 3:00 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences Its Most Comprehensive Study to Date

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has begun its multi-week human clinical hypertension study. The randomized, double blinded, placebo-controlled, cross-over study in 60 people, HYPER-H21-4, is the most comprehensive study ever undertaken by Lexaria. HYPER-H21-4 is designed to enhance Lexaria’s probability of success with its expected subsequent Investigational New Drug (“IND”) application filing to seek U.S. Food and Drug Administration (“FDA”) approval to commence registered clinical testing at phase I level or higher, to be determined in consultation with the FDA. The human study is also expected to enhance Lexaria’s…

Continue Reading